United States - English - NLM (National Library of Medicine)

baxter healthcare corporation - soybean oil (unii: 241atl177a) (soybean oil - unii:241atl177a) - soybean oil 30 g in 100 ml - intralipid® 30% pharmacy bulk package is indicated for use in a pharmacy admixture program for the preparation of three-in-one or total nutrient admixtures (tnas) to provide a source of calories and essential fatty acids for patients requiring parenteral nutrition for extended periods of time (usually for more than 5 days) and as a source of essential fatty acids for prevention of efad. intralipid is contraindicated in patients with: - disturbances of normal fat metabolism such as pathologic hyperlipemia, lipoid nephrosis or acute pancreatitis if accompanied by hyperlipidemia. - known hypersensitivity to egg, soybean, peanut protein, or to any of the active ingredients or excipients in intralipid 30%. intralipid 30% pharmacy bulk package is not intended for direct intravenous administration. diluting intralipid 30% to a 10% or 20% concentration with an intravenous fluid such as normal saline or other diluent does not produce a dilution that is equivalent in composition to intralipid 10% or 20% i.v. fat

United States - English - NLM (National Library of Medicine)

baxter healthcare corp - soybean oil (unii: 241atl177a) (soybean oil - unii:241atl177a) - soybean oil 20 g in 100 ml

United States - English - NLM (National Library of Medicine)

baxter healthcare corporation - soybean oil (unii: 241atl177a) (soybean oil - unii:241atl177a) - soybean oil 20 g in 100 ml - intralipid ®  20% pharmacy bulk package is indicated for use in a pharmacy admixture program for the preparation of three-inone or total nutrition admixtures (tnas) to provide a source of calories and essential fatty acids for patients requiring parenteral nutrition for extended periods of time (usually for more than 5 days) and a source of essential fatty acids for prevention of efad. the administration of intralipid ® is contraindicated in patients with disturbances of normal fat metabolism such as pathologic hyperlipemia, lipoid nephrosis or acute pancreatitis if accompanied by hyperlipidemia. intralipid ®  20% pharmacy bulk package is not intended for direct intravenous administration. diluting intralipid ®  20% to a 10% concentration with intravenous fluid such as normal saline or other diluents does not produce a dillition that is equivalent in composition to intralipid ® 10% i.v. fat emulsion, and such a dilution should not be given by dir

United States - English - NLM (National Library of Medicine)

baxter healthcare corporation - soybean oil (unii: 241atl177a) (soybean oil - unii:241atl177a) - soybean oil 30 g in 100 ml

United States - English - NLM (National Library of Medicine)

hf acquisition co llc, dba healthfirst - soybean oil (unii: 241atl177a) (soybean oil - unii:241atl177a) - intralipid® 20% is indicated as a source of calories and essential fatty acids for patients requiring parenteral nutrition for extended periods of time (usually for more than 5 days) and as a source of essential fatty acids for prevention of efad. the administration of intralipid® 20% is contraindicated in patients with disturbances of normal fat metabolism such as pathologic hyperlipemia, lipoid nephrosis or acute pancreatitis if accompanied by hyperlipidemia. instruction for use - intralipid® 20% container then, then, then, then, then,

United States - English - NLM (National Library of Medicine)

fresenius kabi usa, llc - soybean oil (unii: 241atl177a) (soybean oil - unii:241atl177a) - intralipid® 30% pharmacy bulk package is indicated for use in a pharmacy admixture program for the preparation of three-in-one or total nutrient admixtures (tnas) to provide a source of calories and essential fatty acids for patients requiring parenteral nutrition for extended periods of time (usually for more than 5 days) and as a source of essential fatty acids for prevention of efad. intralipid is contraindicated in patients with: - disturbances of normal fat metabolism such as pathologic hyperlipemia, lipoid nephrosis or acute pancreatitis if accompanied by hyperlipidemia. - known hypersensitivity to egg, soybean, peanut, or any of the active ingredients or excipients in intralipid 30%. intralipid 30% pharmacy bulk package is not intended for direct intravenous administration. diluting intralipid 30% to a 10% or 20% concentration with an intravenous fluid such as normal saline or other diluent does not produce a dilution that is equivalent in composition to intralipid 10% or 20% i.v. fat emulsions,